The distribution of immunoreactivity for the potent vasoconstrictor endothelin-I was studied in adult and developing human gut using antisera to endothelin-1 and the C terminus of big endothelin-1. The coexistence ofthese peptides with other neuropeptides was investigated using comparative immunocytochemistry. Endothelin-I like immunoreactivity was detected in extracts of adult (range 20-60 fmol/g wet weight) and fetal (33 fmol/g) gastrointestinal tract and was shown by chromatography to be the predominant isoform of endothelin present in both. It was localised by immunocytochemistry to ganglion cells in the submucous and myenteric plexuses and to scattered nerves, whereas big endothelin-1 like immunoreactivity was found in the submucous plexus only. Colocalisation studies showed immunoreactivity for both endothelin-1 and vasoactive intestinal peptide in the same ganglion cells of the submucous plexus. Although endothelin-I immunoreactivity was not detected by immunocytochemistry in the fetal human gut until the 32nd week of gestation, big endothelin-I was found as early as 11 weeks in the developing neural structures and epithelial cells. The latter were shown to be endocrine cells by their immunoreactivity for chromogranin. Our results indicate that endothelin is a neuropeptide found in adult human gut which shows transient expression in endocrine cells during development.
Endothelin-1, the first member of a newly discovered mammalian family of biologically active peptides, was originally isolated from the supernatant of cultured porcine endothelial cells.' It is synthesised as a precursor peptide of 203 amino acids, containing a signal sequence, which is subsequently cleaved proteolytically to produce the 38 (human) or 39 (porcine) amino acid intermediate big endothelin-I (big endothelin-1). This is processed further to the mature 21 amino acid form, endothelin-L.' Several isoforms of endothelin-I have been isolated -endothelin-2 and endothelin-3. 23 The latest isoform of the endothelin family to be characterised is a 21 amino acid peptide originally isolated from the guinea pig ileum and termed vasoactive intestinal contractor. Vasoactive intestinal contractor differs from endothelin-1 at three positions (positions 4, 6, and 7), and from endothelin-2 at only one position (position 4).' In addition, these peptides show structural homology with a group of peptide toxins called sarafotoxins from the venom of a snake, the burrowing asp Attactaspis engaddensis.67
Endothelin binding sites are widely distributed, not only in vascular tissues but also in trachea, lung, kidney, gastrointestinal tract, and brain.8 '3 In addition to its vascular location, there is evidence that endothelin-1 also occurs in nerve tissue. It was detected by immunocytochemistry in the paraventricular and supraoptic nuclear neurons and their terminals in the posterior pituitary of the pig and rat,'4 in the neurons of porcine spinal cord, '5 16 in human dorsal root ganglia,'7 and in both glia and neurons within the brain.'8 20 More recently, endothelin-1 immunoreactivity was found in the innervation of the human colon2' where its binding sites were localised to nerves, blood vessels, and muscle.
The aims of this study were (a) to determine the patterns of expression of endothelin-1 and its precursor molecule, big endothelin-1, by immunostaining for both molecular forms in all regions of adult and developing human gut, and (b) to measure the concentrations and molecular forms of endothelin present using radioimmunoassay and chromatography.
Methods

IMMUNOCYTOCHEMISTRY
Histologically normal samples of adult stomach (n=5) (body and antrum), duodenum (n=3), jejunum (n=3), ileum (n=3), colon (n=5), and pancreas (n=4) were removed during surgical excision of tumours. Samples of fetal gastrointestinal tract (stomach, small intestine, and large intestine) from fetuses of 8-32 weeks of gestation were obtained after elective terminations of pregnancy or spontaneous abortion. Tissues were fixed immediately in Bouin's solution for four to 18 hours, washed in 30% (v/v) alcohol, dehydrated through graded alcohols, and embedded in wax. Paraffin sections (3 [tm) were mounted on poly-L-lysine coated slides22 and dried at 37°C overnight.
Antibodies for immunocytochemistry were raised in New Zealand white rabbits using endothelin-1 or big endothelin-l (C terminal [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] with antiserum preabsorbed with synthetic human big endothelin-1 (Peninsula Labs).
Immunostaining with antiserum 2051 could be quenched by addition of big endothelin-1 at a concentration of 0 1 nmol/ml diluted antiserum but only partial absorption of the immunostaining with antiserum 2056 could be obtained. Neither antiserum was affected by addition of endothelin-I at a concentration of 10 nmol/ml. Negative controls included the use of nonimmune serum instead of the primary antiserum or omission of one of the steps in the avidinbiotin complex procedure.
In the adult gut, the possible coexistence of endothelin with neuropeptides was determined using pairs of serial wax sections (3 iim)24
immunostained with antisera to endothelin-I and the major gut neuropeptides -vasoactive intestinal peptide (VIP), neuropeptide Y (NPY), calcitonin gene related peptide (CGRP), and substance P (SP) (see Table I for details). The specificities of the antisera to VIP, NPY, CGRP, and SP, have been reported previously.25 In order to identify cells in the developing gut, a similar procedure was followed using antisera to chromogranin and protein gene product 9-5, gastrin, glucagon, gastric inhibitory polypeptide, secretin, somatostatin-14 and 5-hydroxytryptamine (see Table I ).
RADIOIMMUNOASSAY AND CHROMATOGRAPHY
For radioimmunoassay, pooled samples of adult stomach (antrum and fundus) and rectum and fetal small intestine (17 weeks of gestation) were extracted by boiling in a 10 fold volume of 0-5 mol/l acetic acid for 10 minutes.26 The supernatant was re-extracted using Sep-Pak C18 cartridges (Water Associates, MA, USA) and endothelin like immunoreactivity eluted with 2 ml of 60% (v/v) acetonitrile/water containing 0-026 mol/l ammonium acetate. The eluate was dried in a Savant vacuum centrifuge and the resulting pellet reconstituted with buffer (60 mmol/l phosphate buffer, pH 7-4, containing 7 mmol/l sodium azide and 0-3% (w/v) bovine serum albumin). The recovery of endothelin-1, -2, and -3, which were added to tissues before boiling, was >80%. The antibody to endothelin-1 used for radioimmunoassay was obtained from a subsequent bleed ofan immunoresponsive rabbit27 which gave increased sensitivity. The assay could thus detect changes of 0-05 fmol/ assay tube with duplicate tubes at 95% confidence. The cross reactions with big endothelin (1-38) (Nova Biochem, Nottingham UK), endothelin-2 and endothelin-3 (Peptide Institute, Mono-shi, Japan) were 0-1%, 60%, and 70% respectively. The intra-and interassay In the adult gut, numerous endothelin-1-immunoreactive nerve cell bodies were seen in both submucous (Fig 1) and myenteric ganglia (Fig 2) in all regions examined. The immunoreactivity, localised to the cytoplasm, had a granular appearance. In the submucosa, groups of immunoreactive ganglion cells were mainly found just under the muscularis mucosae or close to the circular muscular layer. In the myenteric ganglia, almost all of the reactive cell bodies were large and ovoid and were at the periphery of the ganglion. Few had the appearance of neuroendocrine cells and were identified as such by immunostaining of chromogranin in serial sections. The frequency of these immunoreactive epithelial cells seemed to increase as gestation proceeded, reaching a peak at around 21 weeks, and they were still present in the oldest fetal gut examined (32 weeks' gestation).
Radioimmunoassay and chromatography Endothelin like immunoreactivity was detected in adult human stomach (60 fmol/g wet weight) and rectum (20 fmol/g) and fetal small intestine (33 fmol/g). FPLC of adult stomach extracts showed three peaks in the positions of the three isoforms of endothelin (Fig 6) . The peak for endothelin-I was slightly greater than that for endothelin-2 while the smallest peak corresponded to the position of endothelin-3. The chromatograph of extracts of fetal small intestine showed only one major peak for endothelin-1 and a much smaller one at the position of endothelin-3 (Fig 7) .
Discussion
This study aimed to determine the presence and localisation of endothelin-1, a newly discovered polypeptide, in the adult and developing human gut using immunocytochemical and biochemical techniques and, with immunocytochemistry, to Escrig, Bishop, Inagaki, Moscoso, Takahashi, Vamndell, Ghatei, Bloom, Polak ,t *1.>" Endothelin-I is one of the most potent vasoconstrictors known and, as well as being present in vascular endothelium,' it has also been found in nervous tissue in different species.""20 In addition, the presence of both endothelin-I like immunoreactivity and binding sites has been detected recently in the adult human colon.2' The results of the present study show that endothelin-1 is the major isoform of endothelin in the adult and fetal human gut and that the peptide is widely distributed in the innervation of most regions of the adult and developing human gut along with its precursor form, big endothelin-1. The findings provide further evidence that endothelin may be a neuropeptide. Only weak immunoreactivity for endothelin-1 was detected in the endothelium. This is probably because of the selection of a tissue processing method that was optimal for demonstration of neural rather than endothelial endothelin-1 immunoreactivity. The same antibody has been found to give satisfactory immunostaining of endothelium in tissue processed in a different way. 21 Immunocytochemistry detected endothelin-1 like immunoreactivity in most ganglion cells of the submucous plexus in all regions of the adult human gastrointestinal tract and in about 10% of those of the myenteric plexus. As shown by the authors in a previous study,2' most submucosal ganglion cells that are immunoreactive for endothelin also contained VIP, a major gut neuropeptide. Since VIP is a potent vasodilator, this coexistence of peptides suggests a possible antagonistic action in the control oflocal blood flow in the gut.
Big endothelin-I like immunoreactivity was detected by immunocytochemistry in the developing human gut as early as 11 weeks of gestation. Although radioimmunoassay showed the presence of endothelin-1 like immunoreactivity in the fetal small intestine at 17 weeks' gestation, it was not detected in nerves until the 32nd week of gestation. Radioimmunoassay detected both endothelial and neural endothelin-1 like immunoreactivity but, for immunocytochemistry, the tissue processing method selected provided optimal preservation of endothelin-l in nerves rather than endothelium. Thus, endothelin-1 may occur in endothelium earlier than in nerves. This may explain the apparent discrepancy between the results obtained by radioimmunoassay and immunocytochemistry. Either way, it seems that the precursor of endothelin-1 is widely expressed in the developing human gut and only to a lesser extent in the adult gut. The change in the predominant form of endothelin immunoreactivity in the fetus, from the precursor to mature endothelin-1, may reflect a change in the post-translational processing of the peptide during development. The exact mechanism causing the switch, possibly the onset of production or activity of a particular converting enzyme, remains to be explained. Immunoreactivities for both endothelin-1 and big endothelin-1 were localised to neural structures in the adult human gut but no immunoreactivity was observed in the mucosal layer. This contrasted with the results obtained in the fetal gut where immunostaining for big endothelin-1 was seen both in neural plexuses and, with antiserum no 2051, in the mucosal epithelium. An epithelial localisation for both endothelin immunoreactivity and mRNA has been reported in the adult rat ileum and colon.27 The presence ofendothelin immunoreactivity in the epithelium may be related to the reported role of the peptide in stimulation of mitogenesis in vitro, which has been shown previously in different systems. [28] [29] [30] In conclusion, endothelin-l is a neuropeptide which, in addition to its endothelial localisation, 
